The ACLY inhibitor bempedoic acid was approved by the FDA in 2020 as a lipid-lowering drug.1294 Furthermore, a series of allosteric ACLY inhibitors with low (nanomolar) competitive inhibitory activity were discovered, such as the allosteric inhibitor NDI-091143, which binds to homotetramer ACLY, shows potent inhibition and is competitive with citrate and noncompetitive with ATP.1295 PF-05221304, an orally administered inhibitor of acetyl-CoA carboxylases (ACC1 and ACC2), is currently undergoing clinical studies (NCT03248882) in nonalcoholic fatty liver disease with fibrosis. Here, BCL2A1 is linked to metabolic dysfunction-associated steatotic liver disease.